We are committed to developing drugs that take a unique approach to precision oncology by focusing on broad mechanisms that have multiple links to oncogenic driver pathways in select patients.
We have developed a diverse pipeline consisting of six distinct programs spanning methyltransferases, kinases, protein-protein interactions, and targeted protein degraders. Our pipeline is geared towards serving patients with high unmet medical need where there are limited or no treatment options.
| Program | Indications | Discovery | IND Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| PR-01 | ||||||
| PRT543 (PRMT5) |
Selected Solid Tumors (Incl. ACC, HRD+) | |||||
| PRT543 (PRMT5) |
Selected Myeloid Malignancies (Incl. MF & MDS) | |||||
| PRT811 (Brain Pentrant PRMT5) |
GBM & CNS Metastatic Cancers | |||||
| PRT1419 (MCL1) |
Selected Hematological Malignancies (oral formulation) | |||||
| PRT1419 (MCL1) |
Solid Tumors (IV formulation) | |||||
| PRT2527 (CDK9) |
Selected Solid & Hematological Malignancies | |||||
| PRT-SCA2 (SMARCA2) |
Multiple Genomically Selected Cancers | |||||
| PRT-K4 (KINASE) |
Solid Tumors | |||||
| Drug | Indication | Stage |
|---|---|---|
| PR-01 | PRT543 (PRMT5) |
Selected Solid Tumors (Incl. ACC, HRD+) | Phase 1 |
| PRT543 (PRMT5) |
Selected Myeloid Malignancies (Incl. MF & MDS) | Phase 1 |
| PRT811 (Brain Pentrant PRMT5) |
GBM & CNS Metastatic Cancers | Phase 1 |
| PRT1419 (MCL1) |
Selected Hematological Malignancies (oral formulation) | IND Enabling |
| PRT1419 (MCL1) |
Solid Tumors (IV formulation) | IND Enabling |
| PRT2527 (CDK9) |
Selected Solid & Hematological Malignancies | IND Enabling |
| PRT-SCA2 (SMARCA2) |
Multiple Genomically Selected Cancers | Discovery |
| PRT-K4 (KINASE) |
Solid Tumors | Discovery |